ClinicalTrials.gg
TerminatedNCT06867094SPECIFI-UCUpdated Oct 21, 2026

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

A Phase 2 interventional study of SAR441566 and SAR441566 matching Placebo in Colitis Ulcerative, sponsored by Sanofi. Terminated at 117 sites in 24 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Why this study was terminated
Business decision
Updated Oct 21, 2026Now TerminatedFirst sites in Croatia and Romania+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Colitis, Ulcerative by Sanofi — 3 open to participants now, 6 under way, 2 of them phase 3. Colitis, Ulcerative · Sanofi.

Enrollment
5th of 12
170 · median 87
Started
2025
with 2 others
Phase 2
8 of 12
none open now
Registered
7th of 12
by date

Among the 12 studies in Colitis, Ulcerative by Sanofi, this one is the 5th largest by enrollment, is one of 3 that started in 2025, is one of 8 in phase 2, and was the 7th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies in Colitis, Ulcerative by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Colitis, Ulcerative by Sanofi, or all of them as a file.
02

Study summary

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.

This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment.

Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study).

  • The study duration will be up to 59 weeks.
  • The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm.
  • The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.
03

Conditions studied

  • Colitis Ulcerative

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Male or female participants aged 18 to 75 years inclusive, at the time of signing the
  • Participants who have clinical evidence of active UC for ≥3 months before screening and confirmed by endoscopy during the screening period
  • Active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician global Assessment (PGA), with a minimum rectal bleeding (RB) subscore ≥1, a minimum stool frequency (SF) subscore ≥1, a mMES ≥2 confirmed by central reader, a minimum sum of all subscores of 5, and a disease extent >15 cm from the anal verge
  • Must have received prior treatment for UC (either "a" or "b" below or a combination of both "a" and "b"):

    1. History of no prior exposure to approved Advanced Therapy (AT), but having inadequate response to, loss of response to or intolerance to standard treatment with any of the following : 5-ASA, thiopurines (eg.6-MP, AZA), MTX, oral or intravenous (IV) or history of corticosteroid dependence (defined an inability to successfully taper corticosteroids without recurrence of UC) OR
    2. History of inadequate response to, loss of response to or intolerance to treatment with ≥1 approved AT such as a biologic agent (eg. TNF antagonists, anti-integrin other than natalizumab, anti-IL-12/23, anti-IL-23, or a small molecule (such as a JAKi or S1PRm) for UC
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participants with active CD, indeterminate colitis, ischemic colitis, microscopic colitis
  • Participants with the following ongoing known complications of UC: fulminant colitis, toxic megacolon, or any other manifestation that might require bowel surgery while enrolled in the study
  • Participant with prior colectomy, ostomy or ileoanal pouch, or anticipated colectomy during their participation in the study
  • Participants with fecal sample positive for ova or parasites, bacterial pathogens, or positive for Clostridium difficile B toxin in stools
  • Participants with active tuberculosis (TB) or a history of incompletely treated active TB or latent TB infection per local guidelines
  • Participants with Positive surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) and/or virus antibody (HCVAb) at the screening visit
  • Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
  • Participants with a known history of (HIV) infection or positive HIV-1 or HIV-2 serology at screening
  • Participants presenting with active , lymphoproliferative disease, or recurrence of either, within the 5 years before screening
  • History of gastro-intestinal dysplasia other than completely removed low grade dysplasia OR presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during endoscopy by the time of the screening visit.
  • If the participant has extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for >10 years, regardless of age, a colonoscopy within 1 year of the screening visit is required to survey for dysplasia. Participants with dysplasia or cancer identified on will be excluded.
  • Female participants who is pregnant, breastfeeding, or is considering becoming pregnant during the study or within 3 months after the last dose of study drug
  • Infection(s) requiring treatment with IV anti-infectives within 30 days prior to the screening visit or oral/intramuscular anti-infectives within 14 days prior to the screening visit
  • Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
  • Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
  • Participants who received fecal microbial transplantation within 30 days prior to screening
  • Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
  • Participants who received IV within 14 days prior to screening or during screening period
  • Screening laboratory and other analyses show abnormal results.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    SAR441566 dose regimen 1

    Participants will receive SAR441566 dose regimen 1

    Drug: SAR441566

  • Experimental
    SAR441566 dose regimen 2

    Participants will receive SAR441566 dose regimen 2

    Drug: SAR441566

  • Experimental
    SAR441566 dose regimen 3

    Participants will receive SAR441566 dose regimen 3

    Drug: SAR441566

  • Placebo comparator
    Placebo

    Participants will receive SAR441566-matching placebo

    Drug: SAR441566 matching Placebo

Interventions

  • Pharmaceutical form: Tablet Route of administration: Oral

  • DrugSAR441566 matching Placebo

    Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving clinical remission at Week 12 by modified Mayo Score (mMS)

    Clinical remission by modified Mayo score (mMS) is defined as a mMS ≤2 with no subscore \>1 (stool frequency \[SF\] of 0 or 1 with at least a 1-point decrease from baseline, rectal bleeding \[RB\] of 0 and modified Mayo Endoscopic Subscore \[mMES\] of 0 or 1 where 1 does not include friability). Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of participants achieving clinical response at Week 12 by modified Mayo Score (mMS)

    Clinical response by modified Mayo score (mMS) is defined as a decrease from baseline in the mMS of ≥2 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1. Each component of the mMS (SF, RB, and mMES) is scored from 0 to 3. The total mMS ranges from 0 to 9 with higher scores indicating greater disease severity.

    Time frame: Week 12

  2. Proportion of participants achieving clinical response at Week 12 by full Mayo score (MS)

    Clinical response by full Mayo score (MS) is defined as a decrease from baseline in the MS of ≥3 points and an improvement of ≥30% from baseline plus a decrease in rectal bleeding (RB) subscore ≥1 or an absolute RB subscore ≤1. The MS (also referred to as the full Mayo Score) is a composite index designed to measure ulcerative colitis (UC) disease activity and consists of 4 subscores: RB and SF, which are patient-reported subscores, Physician's global assessment (PGA), and endoscopic findings. Individual items are rated 0 to 3, giving the composite score a maximum of 12, with higher scores indicating greater disease severity.

    Time frame: Week 12

  3. Proportion of participants achieving clinical remission at Week 12 by full Mayo score (MS)

    Clinical remission by full Mayo score (MS) is defined as a MS ≤2 with no score \>1.

    Time frame: Week 12

  4. Proportion of participants achieving the combination of patient-reported outcome 2 (PRO2) remission and endoscopic remission at Week 12

    Patient-reported outcome 2 (PRO2) remission is defined as PRO2 score ≤1 with rectal bleeding (RB) of 0, and endoscopic remission is defined as mMES of 0. PRO2 score is defined as the sum of Mayo SF and RB subscores.

    Time frame: Week 12

  5. Proportion of participants achieving endoscopic remission at Week 12

    Endoscopic remission is defined as mMES of 0.

    Time frame: Week 12

  6. Change from baseline in PRO2 from randomization to Week 12

    PRO2 score is defined as the sum of the Mayo SF and RB subscores.

    Time frame: From Baseline to Week 12

  7. Proportion of participants achieving endoscopic response at Week 12

    Endoscopic response is defined as mMES decrease of at least 1 point.

    Time frame: Week 12

  8. Proportion of participants achieving endoscopic improvement at Week 12

    Endoscopic improvement is defined as mMES of 0 or 1 where 1 does not include friability.

    Time frame: Week 12

  9. Proportion of participants achieving HEMI at Week 12

    Histologic endoscopic mucosal improvement (HEMI) is defined by achievement of modified Mayo endoscopic improvement (mMES of 0 or 1 where 1 does not include friability) and histological improvement (original Geboes Score \[OGS\] ≤3.1).

    Time frame: Week 12

  10. Plasma predose concentrations of SAR441566 at selected visits

    Time frame: Up to Week 52

  11. Plasma postdose concentrations of SAR441566 at selected visits

    Time frame: Up to Week 52

  12. Number of participants with any treatment-emergent adverse events (TEAEs) during induction and maintenance treatment period

    Time frame: Up to Week 52

  13. Number of participants with any treatment-emergent adverse events (TEAEs) during open-label treatment period

    Time frame: From Week 12 to Week 52

  14. Proportion achieving Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 12

    Inflammatory Bowel Disease Questionnaire (IBDQ) remission is considered as an IBDQ-32 total score ≥170 points. IBDQ is designed to capture the patient's experience of IBD on 4 domains of functioning and well-being: bowel and systemic symptoms and emotional and social function. The total IBDQ score ranges from 32 to 224 which indicates better quality of life.

    Time frame: Week 12

  15. Proportion of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 12

    Inflammatory Bowel Disease Questionnaire (IBDQ) response is defined as an increase from baseline in the total IBDQ score in the range of 16 to 32 points.

    Time frame: Week 12

07

Study locations

117 sites
  • GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400003
    Sun City, Arizona 85351, United States
  • Bristol Hospital- Site Number : 8400017
    Bristol, Connecticut 06010, United States
  • Novum Research- Site Number : 8400018
    Clermont, Florida 34711, United States
  • Clinical Research of Osceola- Site Number : 8400012
    Kissimmee, Florida 34741, United States
  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400002
    Miami Lakes, Florida 33016, United States
  • GCP Clinical Research- Site Number : 8400016
    Tampa, Florida 33609, United States
  • GI Alliance - Glenview- Site Number : 8400005
    Glenview, Illinois 60026, United States
  • Illinois Gastroenterology Group- Site Number : 8400004
    Gurnee, Illinois 60031, United States
  • University of Michigan Health System - Ann Arbor- Site Number : 8400010
    Ann Arbor, Michigan 48109, United States
  • Icahn School of Medicine at Mount Sinai- Site Number : 8400001
    New York, New York 10029, United States
  • Queens Village Primary Medical Center- Site Number : 8400011
    Queens Village, New York 11428, United States
  • NexGen Research- Site Number : 8400020
    Lima, Ohio 45805, United States
  • Frontier Clinical Research - Uniontown- Site Number : 8400006
    Uniontown, Pennsylvania 15401, United States
  • Medical University Of South Carolina - MUSC Health Ashley River Tower - ART- Site Number : 8400008
    Charleston, South Carolina 29401, United States
  • Gastro Health & Nutrition- Site Number : 8400007
    Katy, Texas 77494, United States
  • SI Research Associates- Site Number : 8400019
    Lubbock, Texas 79424, United States
  • Texas Digestive Disease Consultants - Southlake- Site Number : 8400015
    Southlake, Texas 76092, United States
  • University of Washington Medical Center- Site Number : 8400014
    Seattle, Washington 98195, United States
  • Washington Gastroenterology - Tacoma- Site Number : 8400009
    Tacoma, Washington 98405, United States
  • Investigational Site Number : 0320004
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, 1006, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1023, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1061, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1125, Argentina
  • Investigational Site Number : 0360003
    Kurralta Park, South Australia 5037, Australia
  • Investigational Site Number : 0360005
    Richmond, Victoria 3121, Australia
  • Investigational Site Number : 0400002
    Salzburg, 5020, Austria
  • Investigational Site Number : 0400001
    Vienna, 1090, Austria
  • Investigational Site Number : 0560002
    Ghent, 9000, Belgium
  • Investigational Site Number : 0560001
    Leuven, 3000, Belgium
  • Hospital de Clinicas de Porto Alegre- Site Number : 0760002
    Porto Alegre, Rio Grande do Sul 90035903, Brazil
  • Hospital Ernesto Dornelles- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90160-093, Brazil
  • Investigational Site Number : 1000001
    Burgas, 8000, Bulgaria
  • Investigational Site Number : 1000003
    Rousse, 7002, Bulgaria
  • Investigational Site Number : 1000002
    Sofia, 1612, Bulgaria
  • Investigational Site Number : 1240004
    Kentville, Nova Scotia B4N 0A3, Canada
  • Investigational Site Number : 1240006
    Ajax, Ontario L1S 7K7, Canada
  • Investigational Site Number : 1240005
    Richmond Hill, Ontario L4C 9M7, Canada
  • Investigational Site Number : 1240001
    Québec, Quebec G1N 4V3, Canada
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7500010, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 8330034, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8331143, Chile
  • Investigational Site Number : 1560002
    Guangzhou, 510655, China
  • Investigational Site Number : 1560001
    Hangzhou, 310016, China
  • Investigational Site Number : 1560003
    Huizhou, 516001, China
  • Investigational Site Number : 1560017
    Huizhou, 516001, China
  • Investigational Site Number : 1560004
    Jiazhuang, 050000, China
  • Investigational Site Number : 1560014
    Linhai, 317000, China
  • Investigational Site Number : 1560008
    Luoyang, 471003, China
  • Investigational Site Number : 1560005
    Shanghai, 200120, China
  • Investigational Site Number : 1560011
    Wuhan, 430014, China
  • Investigational Site Number : 1910001
    Osijek, 31000, Croatia
  • Investigational Site Number : 2030001
    Olomouc, 779 00, Czechia
  • Investigational Site Number : 2030002
    Ostrava, 710 00, Czechia
  • Investigational Site Number : 2500003
    Nice, 06202, France
  • Investigational Site Number : 2500001
    Toulouse, 31059, France
  • Investigational Site Number : 2500002
    Vandœuvre-lès-Nancy, 54511, France
  • Investigational Site Number : 2680002
    Tbilisi, 0144, Georgia
  • Investigational Site Number : 2680003
    Tbilisi, 0160, Georgia
  • Investigational Site Number : 2680001
    Tbilisi, 0180, Georgia
  • Investigational Site Number : 2760005
    Berlin, 10117, Germany
  • Investigational Site Number : 2760008
    Berlin, 14050, Germany
  • Investigational Site Number : 2760010
    Duisburg, 47055, Germany
  • Investigational Site Number : 2760009
    Frankfurt, 60590, Germany
  • Investigational Site Number : 2760003
    Hanover, 30625, Germany
  • Investigational Site Number : 2760011
    Tübingen, 72076, Germany
  • Investigational Site Number : 2760006
    Ulm, 89081, Germany
  • Investigational Site Number : 3000001
    Athens, 106 76, Greece
  • Investigational Site Number : 3000003
    Athens, 124 62, Greece
  • Investigational Site Number : 3000002
    Heraklion, 711 10, Greece
  • Investigational Site Number : 3480001
    Budapest, Hungary
  • Investigational Site Number : 3560005
    Hyderabad, 500082, India
  • Investigational Site Number : 3560003
    Jaipur, 302001, India
  • Investigational Site Number : 3560009
    Jaipur, 302004, India
  • Investigational Site Number : 3560002
    Kolkata, 700020, India
  • Investigational Site Number : 3560004
    Ludhiana, 141002, India
  • Investigational Site Number : 3560007
    Secunderabad, 500003, India
  • Investigational Site Number : 3560001
    Surat, 395002, India
  • Investigational Site Number : 3560010
    Visakhapatnam, 530040, India
  • Investigational Site Number : 3800006
    Genoa, Genova 16132, Italy
  • Investigational Site Number : 3800002
    Milan, Milano 20132, Italy
  • Investigational Site Number : 3800003
    Rozzano, Milano 20089, Italy
  • Investigational Site Number : 3800008
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800001
    Padua, Padova 35128, Italy
  • Investigational Site Number : 3800011
    Rome, Roma 00161, Italy
  • Investigational Site Number : 3800010
    Turin, Torino 10126, Italy
  • Investigational Site Number : 3800007
    Alessandria, 15100, Italy
  • Investigational Site Number : 3800009
    Palermo, 90127, Italy
  • Investigational Site Number : 3800004
    Pisa, 56124, Italy
  • Investigational Site Number : 3920005
    Kashiwa, Chiba 277-0871, Japan
  • Investigational Site Number : 3920014
    Kure, Hiroshima 737-0811, Japan
  • Investigational Site Number : 3920003
    Sapporo, Hokkaido 004-0041, Japan
  • Investigational Site Number : 3920007
    Sapporo, Hokkaido 065-0033, Japan
  • Investigational Site Number : 3920009
    Yahaba, Iwate 028-3695, Japan
  • Investigational Site Number : 3920013
    Yokohama, Kanagawa 220-0041, Japan
  • Investigational Site Number : 3920002
    Bunkyo-Ku, Tokyo 113-8510, Japan
  • Investigational Site Number : 3920011
    Kodaira, Tokyo 187-8510, Japan
  • Investigational Site Number : 3920006
    Kofu, Yamanashi 400-0027, Japan
  • Investigational Site Number : 3920012
    Hiroshima, 734-8530, Japan
  • Investigational Site Number : 3920016
    Kagoshima, 892-0843, Japan

Showing the first 100 of 117 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Aug 2026, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 10, 2025
StartActual
Mar 28, 2025
Primary completionActual
Aug 6, 2026
CompletionActual
Oct 12, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Business decision
changed Oct 21, 2026
Sites
3 sites added, 1 site removed — first sites in Croatia and Romania
Show 3 added (1 Canada, 1 Croatia, 1 Romania)
  • Investigational Site Number : 1240006 · Ajax, Canada
  • Investigational Site Number : 1910001 · Osijek, Croatia
  • Investigational Site Number : 6420001 · Constanța, Romania
Show 1 removed
  • Investigational Site Number : 0400003 · Graz, Austria
Sep 25, 2026
Study completion
Oct 14, 2026→Oct 12, 2026 (actual)
Oct 21, 2026
Enrollment
204 (estimated)→170 (actual)
Oct 21, 2026
Show all 2 updates
  1. Oct 21, 2026
    Active, not recruiting→Terminated
    Why stopped Business decision
    Study completion Oct 14, 2026→Oct 12, 2026 (now actual)
    Enrollment 204 (estimated)→170 (actual)
    + 1 other change: verification date
  2. Sep 25, 2026
    3 sites added, 1 site removed — first sites in Croatia and Romania
    Show 3 added (1 Canada, 1 Croatia, 1 Romania)
    • Investigational Site Number : 1240006 · Ajax, Canada
    • Investigational Site Number : 1910001 · Osijek, Croatia
    • Investigational Site Number : 6420001 · Constanța, Romania
    Show 1 removed
    • Investigational Site Number : 0400003 · Graz, Austria

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06867094
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 10, 2025
Start date
Mar 28, 2025
Primary completion
Aug 6, 2026
Completion
Oct 12, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balinatunfib

Start the discussion